Kamiya Kazutaka, Kanayama Shunsuke, Takahashi Masahide, Shoji Nobuyuki
Visual Physiology, School of Allied Health Sciences, Kitasato University, Kanagawa 252-0373, Japan.
Department of Ophthalmology, School of Medicine, Kitasato University, Kanagawa 252-0374, Japan.
J Clin Med. 2020 Oct 8;9(10):3222. doi: 10.3390/jcm9103222.
Customized cross-linking has been proposed as an alternative to conventional cross-linking in patients with progressive keratoconus, targeting greater flattening of the cone region and improved visual function. Epithelium-on cross-linking aims to reduce complications associated with epithelial removal, while the addition of oxygen aims to maintain treatment effect. Our study evaluates the combination of these novel treatment strategies to achieve a minimally invasive treatment targeting maximal functional outcomes. This prospective study included 42 eyes undergoing epithelium-on, accelerated, oxygen-supplemented, customized corneal cross-linking for progressive keratoconus. Outcome measures, including refraction, visual acuity, and corneal tomography were obtained at baseline and at 1, 3, and 6 months, and 1 year postoperatively. Logarithm of the minimum angle of resolution (logMAR) uncorrected visual acuity was significantly improved, from 0.87 ± 0.53 preoperatively, to 0.78 ± 0.56 1 year postoperatively (Wilcoxon rank sum test, = 0.016). LogMAR best spectacle-corrected visual acuity was also significantly improved, from 0.19 ± 0.36 preoperatively, to 0.11 ± 0.33 postoperatively ( = 0.004). Manifest refractive cylinder was significantly decreased, from 4.50 ± 2.96 D preoperatively, to 3.27 ± 2.61 D postoperatively ( = 0.004). The baseline maximum keratometry (Kmax) was 53.04 ± 7.91 D, significantly flattening to 52.25 ± 7.31 D by 1 month, and remaining relatively stable at 1 year postoperatively (52.31 ± 7.50 D) ( < 0.001). No significant adverse events occurred in any eye. Epithelium-on, accelerated, oxygen-supplemented, customized corneal cross-linking is a promising new treatment approach, with reduced maximum keratometry, reduced astigmatism, and improved visual acuity at 1 year, with a favorable safety and patient comfort profile.
对于进行性圆锥角膜患者,定制交联已被提议作为传统交联的替代方法,目标是使圆锥区域更大程度变平并改善视觉功能。上皮在位交联旨在减少与上皮去除相关的并发症,而添加氧气旨在维持治疗效果。我们的研究评估了这些新型治疗策略的组合,以实现针对最大功能结果的微创治疗。这项前瞻性研究纳入了42只接受上皮在位、加速、补充氧气、定制角膜交联治疗进行性圆锥角膜的眼睛。在基线、术后1个月、3个月、6个月和1年时获取了包括验光、视力和角膜地形图在内的结果指标。最小分辨角对数(logMAR)未矫正视力从术前的0.87±0.53显著提高到术后1年的0.78±0.56(Wilcoxon秩和检验,P = 0.016)。logMAR最佳矫正视力也从术前的0.19±0.36显著提高到术后的0.11±0.33(P = 0.004)。明显的屈光柱镜度数从术前的4.50±2.96 D显著降低到术后的3.27±2.61 D(P = 0.004)。基线最大角膜曲率(Kmax)为53.04±7.91 D,到1个月时显著变平至52.25±7.31 D,并在术后1年相对稳定(52.31±7.50 D)(P < 0.001)。任何一只眼睛均未发生明显不良事件。上皮在位、加速、补充氧气、定制角膜交联是一种有前景的新治疗方法,在1年时最大角膜曲率降低、散光减少且视力改善,安全性良好且患者舒适度高。